Archives
- 2018-07
- 2018-10
- 2018-11
- 2019-04
- 2019-05
- 2019-06
- 2019-07
- 2019-08
- 2019-09
- 2019-10
- 2019-11
- 2019-12
- 2020-01
- 2020-02
- 2020-03
- 2020-04
- 2020-05
- 2020-06
- 2020-07
- 2020-08
- 2020-09
- 2020-10
- 2020-11
- 2020-12
- 2021-01
- 2021-02
- 2021-03
- 2021-04
- 2021-05
- 2021-06
- 2021-07
- 2021-08
- 2021-09
- 2021-10
- 2021-11
- 2021-12
- 2022-01
- 2022-02
- 2022-03
- 2022-04
- 2022-05
- 2022-06
- 2022-07
- 2022-08
- 2022-09
- 2022-10
- 2022-11
- 2022-12
- 2023-01
- 2023-02
- 2023-03
- 2023-04
- 2023-05
- 2023-06
- 2023-08
- 2023-09
- 2023-10
- 2023-11
- 2023-12
- 2024-01
- 2024-02
- 2024-03
- 2024-04
- 2024-05
- 2024-06
- 2024-07
- 2024-08
- 2024-09
- 2024-10
- 2024-11
- 2024-12
- 2025-01
- 2025-02
- 2025-03
-
Regarding their reported beneficial properties
2021-05-25
Regarding their reported beneficial properties on the digestive tract, the aim of this study was to evaluate the effect of water extracts of three Hypericum sps., HP, HA, HU and some of the main phenolic compounds (Ch, R and Q) on DNA protection against oxidative and alkylating DNA damage induced by
-
Based on the deduced amino acid sequence of the catalytic
2021-05-25
Based on the deduced amino Tricine sequence of the catalytic subunit of rG3DH, we could find sequence features that are highly conserved in FAD-harboring dehydrogenase, which include FAD binding motif and sequential cysteine residues in Cysteine-rich region. Several dehydrogenases share similarity
-
Introduction Tumor necrosis factor TNF
2021-05-25
Introduction Tumor necrosis factor (TNF) is a pro-inflammatory mediator with the capacity to induce apoptosis (Benderska et al., 2012). Recent reports have shown that TNF might trigger cell death, at least in part, by directly affecting the reorganization of the Geneticin australia cytoskeleton (C
-
The pharmacokinetics properties of compound were evaluated
2021-05-25
The pharmacokinetics properties of compound were evaluated in male Sprague Dawley rats following IV (0.7mg/kg) and oral (2.0mg/kg) dosing. The total body clearance and the terminal half-life were 0.73 L/h/kg and 5.1h, respectively. After oral administration the compound showed good bioavailability
-
Within the Class II receptors the Type
2021-05-25
Within the Class II receptors, the Type I IFN receptor subunit, IFNAR-1, is exceptional in having four tandem FNIII domains, denoted here D1–D4. This structure appears to have arisen as a tandem orphan receptor of the basic D1/D2 structure; thus, D1 and D3 of IFNAR-1 are more closely related, as ar
-
Materials and methods br Results br Discussion Microbial pro
2021-05-25
Materials and methods Results Discussion Microbial production of trans-4Hyp, an added-value amino Kisspeptin 234 for pharmaceuticals, offers significant advantages over conventional chemical extraction in economic and environmental aspects. However the low titer and productivity with the exi
-
br Experimental br Results and discussion On the basis
2021-05-25
Experimental Results and discussion On the basis of the information obtained from the studies on RHA/TiO2 nanocomposites, it Topiroxostat receptor is expected that this reagent can be used as a catalyst for the promotion of the organic reactions. So this reagent was used in the promotion of t
-
The biological actions of ET are
2021-05-24
The biological actions of ET‐1 are mediated via two distinct receptor subtypes, the endothelin A and endothelin B receptors (ETA/ETB). While activation of ETA is assumed to mediate contraction of smooth muscle cells, the activity of ETB is related to transient vasodilation [22]. In human corpus cave
-
The different serotypes A G have unique receptors to which
2021-05-24
The different serotypes (A-G) have unique receptors to which they bind to produce the toxic effect on the nerve cells. (Lance, 2004, Rosetto et al., 2014). Intracellularly, the endopeptidase activity of different serotypes of BoNT target selectively a unique group of proteins, the SNARE thyrotropin
-
As mentioned above EBI and its ligand show
2021-05-24
As mentioned above, EBI2 and its ligand show some similarities to the sphingosine 1-phosphate (S1P)/S1P-receptor system, which mediates T cell egress from lymph nodes. Blockade of this system yielded in the first oral drug for MS patients named fingolimod. Therefore, the hope that EBI2 deficiency wo
-
In humans several different small ubiquitin related modifier
2021-05-24
In humans, several different small ubiquitin-related modifier (SUMO) paralogs can be conjugated to cellular proteins. The human genome codes for five SUMO paralogs (SUMO1–5); of these, SUMO1 and the almost identical SUMO2 and SUMO3 are ubiquitously expressed. Sumoylation is executed by an enzymatic
-
Several functions of FAT have been suggested It has been
2021-05-24
Several functions of FAT10 have been suggested. It has been shown that FAT10 binds noncovalently to the mitotic spindle checkpoint protein MAD2 and that this binding might cause chromosome instability in the cancer ccr2 inhibitor overexpressing FAT10 (Liu et al., 1999, Ren et al., 2006). In other st
-
br Conclusions The PQQ dependent CcPDH is
2021-05-24
Conclusions The PQQ-dependent CcPDH is the first PQQ-dependent enzyme identified in eukaryotes. The PQQ cofactor binds the enzyme with high affinity, reflected in a Kd of 1.1 nM, and the enzyme oxidizes 2KG, l-fucose, and rare sugars such as d-arabinose and l-galactose. The AA8 cytochrome b domai
-
mmp endocrinology Our finding that activating DDR variants a
2021-05-24
Our finding that activating DDR2 variants are a cause of this disease suggested that the ABL inhibitor dasatinib, a leukemia drug that also inhibits DDR2, could be used for treatment of affected individuals.10, 11 To examine the effect of dasatinib on p.Leu610Pro- and p.Tyr740Cys-induced autophospho
-
Henderson et al reported that allergen
2021-05-24
Henderson et al. [20] reported that allergen-induced airway remodeling was blocked by the CysLT1 receptor antagonist montelukast. The development of epithelial thickening and mucus accumulation at relatively small bronchi was also suppressed by montelukast. The CysLT2 receptor antagonist BayCysLT2RA
15850 records 631/1057 page Previous Next First page 上5页 631632633634635 下5页 Last page